These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33508690)

  • 1. Within-subject evaluation of interim buprenorphine treatment during waitlist delays.
    Oleskowicz TN; Ochalek TA; Peck KR; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2021 Mar; 220():108532. PubMed ID: 33508690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.
    Sigmon SC; C Meyer A; Hruska B; Ochalek T; Rose G; Badger GJ; Brooklyn JR; Heil SH; Higgins ST; Moore BA; Schwartz RP
    Addict Behav; 2015 Dec; 51():136-42. PubMed ID: 26256469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults.
    Peck KR; Ochalek TA; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2020 Mar; 208():107879. PubMed ID: 31991327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technology-Assisted Buprenorphine Treatment in Rural and Nonrural Settings: Two Randomized Clinical Trials.
    Sigmon SC; Peck KR; Batchelder SR; Badger GJ; Heil SH; Higgins ST
    JAMA Netw Open; 2023 Sep; 6(9):e2331910. PubMed ID: 37755833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.
    Streck JM; Ochalek TA; Badger GJ; Sigmon SC
    Exp Clin Psychopharmacol; 2018 Aug; 26(4):403-409. PubMed ID: 29939049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of an interactive voice response system for daily monitoring of illicit opioid use during buprenorphine treatment.
    Parker MA; Ochalek TA; Rose GL; Badger GJ; Sigmon SC
    Psychol Addict Behav; 2018 Dec; 32(8):956-960. PubMed ID: 30359047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: A pilot study.
    Ochalek TA; Heil SH; Higgins ST; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2018 Sep; 190():224-228. PubMed ID: 30056321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study.
    Scott TM; Rivera Mindt M; Cunningham CO; Arias F; Coulehan K; Mangalonzo A; Olsen P; Arnsten JH
    Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):48. PubMed ID: 29141650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
    Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
    Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim buprenorphine treatment in opiate dependence: A pilot effectiveness study.
    Abrahamsson T; Widinghoff C; Lilliebladh A; Gedeon C; Nilvall K; Hakansson A
    Subst Abus; 2016; 37(1):104-9. PubMed ID: 26176490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Current Pain Status on Low-Barrier Buprenorphine Treatment Response Among Patients with Opioid Use Disorder.
    Peck KR; Ochalek TA; Streck JM; Badger GJ; Sigmon SC
    Pain Med; 2021 May; 22(5):1205-1212. PubMed ID: 33585885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder.
    Bhatraju EP; Radick AC; Leroux BG; Kim TW; Samet JH; Tsui JI
    Am J Drug Alcohol Abuse; 2023 Jul; 49(4):511-518. PubMed ID: 37369019
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim treatment: Bridging delays to opioid treatment access.
    Sigmon SC
    Prev Med; 2015 Nov; 80():32-6. PubMed ID: 25937593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of naltrexone in treating opioid use disorder in pregnancy.
    Towers CV; Katz E; Weitz B; Visconti K
    Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.
    Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM
    Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
    Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
    JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.